The articles discusses about the patients with multiple myeloma on receiving cilta-cel. Topics include patients exposed to immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody; 42.3% were penta-drug refractory, and 99% were refractory to their most recent line of therapy.